Today: 23 June 2026
Browse Category

Pharmaceuticals 14 January 2026 - 16 January 2026

AbbVie is acquiring Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal is expected to close in the third quarter and will bring AbbVie zumilokibart, an experimental long-acting drug for atopic dermatitis and other immune diseases. Apogee claims its top eczema drug could significantly reduce injection frequency compared to Dupixent, with Phase 3 trials planned for this year. Pfizer shares declined over the past week after CFO Dave Denton announced he will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession, execution, and competition from obesity-drug makers. Pfizer’s stock has also been affected by concerns over pricing pressure, patent cliffs, and a longer path to profitability in obesity drugs. Meanwhile, Novo Nordisk shares rose about 5% as healthcare stocks gained favor among investors seeking defensive positions, even as the company reported strong demand for its Wegovy pill. Alumis shares surged 15.55% ahead of Phase 2b lupus results due in the third quarter and a planned psoriasis NDA filing in the fourth quarter. Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected on July 29. Other notable moves include AtaiBeckley’s 7.8% rise following the start of its BPL-003 Phase 3 program and CervoMed’s premarket jump after a director-linked trust purchased $3 million in units, following a recent $10.5 million private placement.
PainReform PRFX stock jumps in premarket after company rebrands as PRF Technologies

PainReform PRFX stock jumps in premarket after company rebrands as PRF Technologies

PainReform shares rose about 13% in premarket trading after the company announced it has rebranded as PRF Technologies Ltd, keeping its Nasdaq ticker PRFX. The firm said it will expand beyond pain therapy into drug delivery and solar analytics. The announcement was filed with the SEC on Thursday. PRF Technologies continues to advance its PRF-110 pain treatment and LayerBio’s OcuRing-K ocular therapy.
16 January 2026
··
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly shares fell 3.8% premarket to $1,033 after FDA documents set an April 10 decision date for its weight-loss pill under a fast-track program. Strive Specialties sued Lilly and Novo Nordisk in Texas, alleging efforts to block cheaper compounded GLP-1 drugs. Novo Nordisk shares dropped 3%. Investors await further FDA guidance and Lilly’s Feb. 4 earnings call.
16 January 2026
··
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly shares fell 3.8% to $1,032.97 in after-hours trading after the FDA delayed its decision on the company’s obesity pill to April 10. A Texas compounding pharmacy filed a new lawsuit against Lilly and Novo Nordisk, alleging efforts to block access to cheaper alternatives. Investors are watching Lilly’s Feb. 4 earnings call and the FDA’s April decision as key dates.
15 January 2026
··
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares rose 0.3% to $25.67 Thursday as investors weighed U.S. vaccine policy debates and the company’s growth outlook. The stock moved between $25.26 and $25.67 with 22.3 million shares traded. Pfizer will report Q4 results on Feb. 3, with guidance projecting 2026 revenue of $59.5–$62.5 billion and lower COVID-19 product sales. Competition in obesity drugs and AI-driven drug discovery remain in focus.
15 January 2026
····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck shares closed up 2.54% at $111.01 Wednesday, outperforming a falling U.S. market. Management raised forecasts for new drugs, projecting $70 billion in revenue from growth drivers by the mid-2030s. CEO Rob Davis said Merck has capacity for major deals and is running 80 phase three trials. Investors are watching for Feb. 3 earnings to assess the 2026 outlook.
15 January 2026
···
AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie shares rose about 0.5% to $221.89 in after-hours trading Wednesday after executives outlined plans to expand into obesity treatments. The company is betting on GUBamy, a drug licensed from Denmark’s Gubra, and highlighted its focus on amylin-based therapies. Investors are watching for pricing pressure from Washington ahead of AbbVie’s Feb. 4 earnings report.
15 January 2026
··
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly shares fell about 0.3% in after-hours trading Wednesday after the FDA asked drugmakers to remove suicide-risk warnings from GLP-1 weight-loss drugs. The agency found no link between the drugs and increased suicide risk. Investors are watching Lilly’s plans for its oral obesity drug, orforglipron, which could launch soon at a $150 monthly price.
15 January 2026
··
Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson shares rose 2.3% to $218.55 in after-hours trading Wednesday after reporting its Tecvayli drug cut the risk of disease progression or death by 71% in a late-stage multiple myeloma trial. An independent committee recommended unblinding the study. Full results will be presented at an upcoming medical meeting. Investors await the company’s quarterly results next week.
15 January 2026
···
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer shares rose 2% to $25.65 Wednesday after CEO Albert Bourla said the company is “all in on obesity” and plans 10 Phase 3 trials for its Metsera compounds by 2026. Pfizer does not expect revenue growth to return until 2029 as it faces patent expirations and weaker COVID-related sales. AbbVie also announced new obesity drug plans. Novo Nordisk warned of tougher competition in 2026.
14 January 2026
···
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares rose 10.4% to $38.03 by midday Wednesday after the company announced 2026 targets for its chronic myeloid leukemia drug at the JPMorgan Healthcare Conference. The company plans a pivotal dose selection and an FDA meeting by mid-2026, following early trial data showing a 75% major molecular response at 24 weeks. Investors are watching for longer-term results and regulatory milestones.
14 January 2026
··
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer shares rose 1.4% to $25.51 Wednesday morning, outpacing a broader market decline. CEO Albert Bourla said the company misjudged the cash-pay obesity drug market and plans about 10 Phase 3 obesity trials in 2026. Investors are watching for Feb. 3 results and updates on late-stage trial launches. Pfizer expects no revenue growth before 2029 as it faces major patent expirations.
14 January 2026
·····
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly shares fell about 0.4% Wednesday after the FDA ordered drugmakers to remove suicidality warnings from obesity drugs including Zepbound. The FDA said its review found no increased risk of suicidal thoughts with GLP-1 drugs. Investors are watching for updates on Lilly’s oral obesity pill ahead of the Feb. 4 earnings call.
14 January 2026
···
1 … 15 16 17 18 19 … 42

Stock Market Today

  • Talon Resources PLC Cancelled from London Stock Exchange Following AIM Transfer
    June 23, 2026, 3:49 AM EDT. Talon Resources PLC has been removed from trading on the London Stock Exchange, effective June 23, 2026. This follows the company's transfer to AIM, the Alternative Investment Market, a sub-market designed for smaller, growing companies. The cancellation affects ordinary shares of GBP 0.01 each. Investors holding these shares should note the change. The London Stock Exchange's Regulatory News Service provided the update and is authorized by the Financial Conduct Authority to disseminate primary market information in the UK.

Latest articles

Amazon Stock Just Got Hit Before Prime Day — AI Spending Fears Are Back

Amazon Stock Just Got Hit Before Prime Day — AI Spending Fears Are Back

23 June 2026
Amazon shares plunged 4.75% to $232.79 as investors questioned whether the company’s massive AI and cloud spending will pay off quickly enough, just ahead of Prime Day—a key test of U.S. consumer demand—with Bank of America projecting $21.6 billion in sales for the event and analysts warning that profit quality could disappoint if shoppers focus on lower-margin essentials.
Keel Shares Hit Record—What’s Next for the Stock

Keel Shares Hit Record—What’s Next for the Stock

23 June 2026
Keel Infrastructure Corp. surged 5.9% to a 52-week high as investors bet its power sites can be converted to AI data-center leases, with shares ending at $6.66 on heavy volume; the stock’s rally now hinges on permits, construction, and landing customer contracts, while upcoming Russell 3000 index inclusion and recent $458 million convertible note financing add both opportunity and dilution risk.
Go toTop